Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saruparib in Advanced Solid Malignancies
NCT06899061Phase 1Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, randomised, open-label trial of saruparib in malignant solid tumor (3 cohorts), sponsored by AstraZeneca. Primary endpoints: Area under plasma concentration-time curve from zero extrapolated to infinity, Area under the plasma concentration curve from zero to the last quantifiable concentration and 1 more. Started Mar 2025; status: active, not recruiting.
02
Drugs
saruparib
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT06899061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06899061.